Iron Mountain Inc vs Mesoblast Limited — how do they compare? Iron Mountain Inc trades at $126.07 (market cap $36.96B), while Mesoblast Limited trades at $16.32 (market cap $2.17B). The key difference: Iron Mountain Inc is far larger — about 17× Mesoblast Limited's market cap, and Iron Mountain Inc pays a 2.78% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| IRM | MESO | |
|---|---|---|
Market Cap | $36.96B | $2.17B |
Sector | Real Estate | Technology |
52-Week High | $133.06 | $20.96 |
52-Week Low | $78.86 | $12.88 |
Enterprise Value | $56.10B | $2.17B |
Dividend Yield | 2.78% | — |
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $124.38, up 0.45% for the day, with a bullish technical signal and strong recent earnings beats. The stock has rallied 30.2% over three months, supported by data center growth and recurring storage revenue. However, the company faces high debt levels, with a debt-to-asset ratio of 74.39% in 2024, and a P/E ratio of 134.59 suggests elevated valuation. Analyst consensus is bullish with a $138.67 price target, though the RSI_6 at 84.86 indicates potential overbought conditions near-term.
Outlook remains positive due to consistent earnings outperformance and data center expansion, but risks include significant leverage and declining paper storage demand. The stock offers a dividend yield with a recent $0.86 payment, yet investors should weigh high valuation multiples against growth prospects in a competitive information services sector.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Trailing returns across standard periods
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →